RoboSense Wins GOLD 2019 Stevie Award
RoboSense (Suteng Innovation Technology Co., Ltd) www.robosense.ai, a leader in LiDAR perception technology solutions, announced today that it has won the GOLD 2019 Stevie ® Award in the “Transportation Category” for the RoboSense Automotive Grade MEMS LiDAR Perception System. The award will be given out at the 17 th Annual Stevie Awards - American Business Awards ® , to be held in NY City on June 11, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190507005708/en/
RS-LiDAR-M1, RoboSense Automotive Grade MEMS LiDAR Perception System's Sensor (Photo: Business Wire)
The RoboSense Automotive Grade MEMS LiDAR Perception System is a revolutionary automotive solution that makes autonomous driving safer, easily mass produced, and lower cost. In addition to the Stevie Award, the RoboSense system is a CES 2019 Innovation Award winner. The system includes automotive grade MEMS solid-state LiDAR RS-LiDAR-M1 and RoboSense’s unique perception RS-LiDAR-Algorithms for a complete system that lets the vehicle understand the road environment for safer autonomous driving. RoboSense’s system offers ground-breaking mass production-ready hardware and software based vehicle environmental perception to support Level 3 to Level 5 autonomous driving at a fraction of the cost.
In preparation for autonomous vehicle mass market growth, RoboSense recently launched the Smart Sensor System (SSS), which combines RoboSense LiDAR sensors, AI point cloud algorithms, and an IC design for chip development. Created for four key smart transportation vehicle applications: autonomous passenger cars, low-speed autonomous vehicles, high-speed RoboTaxis, and V2R (Vehicle to Road infrastructure), the RoboSense Smart Sensor System is a smarter information interpreter that collects and interprets environmental information in one-stop for safer and more intelligent autonomous driving.
Stevie Award Judges Say RoboSense System “will take autonomous driving to the next level” “Impressive product with great growth potential”
A Stevie Award judge said the “MEMS LiDAR Perception System costs 1/500th the cost of mechanical LiDAR and provides higher resolution and better field of view. With intelligence perception algorithms, it can clearly recognize small objects, such as railings and fences and works in all weather conditions and at night and has no blind zone. It is automotive grade and has longer detection distance, making it ideal for autonomous solutions.” Another judge said it is “the best performer in the category and will take autonomous driving to the next level.” And another judge concluded, the RoboSense System is “Innovative technology which cuts costs and improves performance greatly. This has everything in its favor and offers the complete package for next generation vehicles.”
More than 3,800 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. The American Business Awards are the U.S.A.’s premier business awards program. More than 200 professionals worldwide participated in the judging process to select this year’s Stevie Award winners.
“We are honored to be recognized by the prestigious American Business Awards for our innovative LiDAR technology that propels autonomous driving into mass production for use by everyone, from passenger cars, RoboTaxis, logistics vehicles, shuttle buses, and more,” said Mark Qiu, Co-Founder & COO, RoboSense.
“The nominations submitted to The 2019 American Business Awards were outstanding. They illustrate the continued vibrancy of innovation and high level of achievement across the American economic landscape,” said Michael Gallagher, president and founder of the Stevie Awards.
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading LiDAR environment perception solutions provider and developer of LiDAR hardware, AI point cloud algorithms, and IC designs. Founded in 2014, RoboSense has over 500 employees in six locations, including the U.S., Shenzhen, Beijing, Shanghai, and Germany. Focusing on the strategic deployment of smart sensor systems, RoboSense has developed a variety of application solutions based on LiDAR hardware technologies and algorithms. In five years, RoboSense has already released 18 products and technical solutions, and has applied for more than 400 patents.
RoboSense has a variety of product lines, including MEMS solid-state LiDAR and Mechanical LiDAR smart sensor systems. Customers include the world’s major autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers. RoboSense LiDAR solutions have been widely used in various application scenarios, such as self-driving logistics vehicles, buses, passenger cars, and more. For more information, see https://www.robosense.ai.
About the Stevie Awards
Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 07:00:00 EEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 04:00:00 EEST | Press release
Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom